<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Next Epoch News — Genetics &amp; Medicine</title>
    <link>https://nextepochnews.com/genetics-medicine/</link>
    <description>Genetics, therapies, and biomedical tools, reported with limits and stage in plain view.</description>
    <language>en</language>
    <lastBuildDate>Fri, 20 Nov 2026 08:00:00 GMT</lastBuildDate>
    <atom:link href="https://nextepochnews.com/genetics-medicine/feed.xml" rel="self" type="application/rss+xml"/>
    <item>
      <title>Personalized mRNA vaccine plus pembrolizumab cuts melanoma recurrence in phase 3</title>
      <link>https://nextepochnews.com/genetics-medicine/interpath-001-melanoma-mrna-vaccine/</link>
      <guid isPermaLink="true">https://nextepochnews.com/genetics-medicine/interpath-001-melanoma-mrna-vaccine/</guid>
      <pubDate>Fri, 20 Nov 2026 08:00:00 GMT</pubDate>
      <description>In a randomized phase 3 trial of 1,137 patients with resected high-risk melanoma, adding an individualized neoantigen mRNA therapy to pembrolizumab improved recurrence-free and distant-metastasis-free survival.</description>
      <category>Genetics &amp; Medicine</category>
    </item>
  </channel>
</rss>
